ARROWHEAD PHARMACEUTICALS, INC.
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is a biopharmaceutical company focused on developing RNA interference-based therapeutics designed to silence disease-causing genes. The company's proprietary Targeted RNAi Molecule (TRiM) platform utilizes ligand-mediated delivery to enable tissue-specific targeting of… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What ARROWHEAD PHARMACEUTICALS, INC. does
In the company’s own words
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is a biopharmaceutical company focused on developing RNA interference-based therapeutics designed to silence disease-causing genes. The company's proprietary Targeted RNAi Molecule (TRiM) platform utilizes ligand-mediated delivery to enable tissue-specific targeting of siRNA therapeutics across multiple cell types and tissues throughout the body. This platform represents a significant advancement in RNAi technology, allowing the company to address previously "undruggable" gene targets across diverse therapeutic areas.
The company achieved a transformational milestone in 2025 with FDA approval of REDEMPLO (plozasiran), its first commercial product, indicated as an adjunct to diet to reduce triglycerides in adults with Familial Chylomicronemia Syndrome. REDEMPLO works by suppressing apolipoprotein C-III production in the liver, delivering significant triglyceride reductions. The company has built a commercial organization to support marketing in this rare disease and plans to expand capabilities to support additional indications, including severe hypertriglyceridemia, pending successful completion of Phase 3 clinical studies.
Arrowhead maintains a robust pipeline of 18 drug candidates in clinical trials ranging from Phase 1 to Phase 3, with programs targeting dyslipidemia, metabolic disorders, neurological diseases, renal diseases, and rare genetic conditions. The company has strategically partnered with leading pharmaceutical and biotech companies including Sarepta Therapeutics, Amgen, Takeda, GlaxoSmithKline, and Novartis to develop programs outside its core focus areas, generating non-dilutive capital to support wholly-owned programs through commercialization.
The company controls approximately 643 issued patents and 833 pending patent applications across 103 patent families worldwide, providing substantial intellectual property protection for its RNAi trigger molecules, delivery technologies, and platform innovations. Arrowhead's business model combines internal development of lead programs with strategic licensing arrangements, enabling the company to maximize the potential of its differentiated TRiM platform while managing capital efficiently across its diverse pipeline of genetic disease treatments.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- PASADENA, CA
- Fiscal year end
- September
- CIK
- 879407
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns ARROWHEAD PHARMACEUTICALS, INC. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in ARROWHEAD PHARMACEUTICALS, INC. · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · ARROWHEAD PHARMACEUTICALS, INC.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
ARROWHEAD PHARMACEUTICALS, INC.’s bonds, as funds hold them
Funds report holding 1 issues of ARROWHEAD PHARMACEUTICALS, INC.’s debt, $93.19M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 0.00%, maturing 2032 to 2032.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do ARROWHEAD PHARMACEUTICALS, INC. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of ARROWHEAD PHARMACEUTICALS, INC.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in ARROWHEAD PHARMACEUTICALS, INC.'s last four quarterly filings that the numbers alone won't show?”